Rhino Propels Federated AI into the Enterprise Tech Stack Hitachi Energy launches the next-generation TXpert solution to digitalize every transformer
ZURICH, SWITZERLAND, Feb 23, 2023 – (JCN Newswire) – Hitachi Energy, a global technology leader…
Gotion High-Tech Wins Volkswagen Cell Test Lab Qualification
HONG KONG, Feb 23, 2023 – (ACN Newswire) – On February 21, Gotion High-tech was…
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or…
DelphX Announces Non-Brokered Unit Financing
Toronto, Ontario–(Newsfile Corp. – February 22, 2023) – DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB:…
Samsung Electronics Introduces Standardized 5G NTN Modem Technology to Power Smartphone-Satellite Communication
Standardized 5G NTN technology simulated on Samsung’s Exynos Modem 5300; Demonstrates two-way text messaging as…
Eastman Announces Pricing of $500 Million 5.750% Notes due 2033 in Inaugural Green Bond Offering
KINGSPORT, Tenn.–(BUSINESS WIRE)–Eastman Chemical Company (NYSE: EMN) today announced the pricing of its public offering…
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal…
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve…
Jounce Therapeutics Announces Restructuring
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage…
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
Over 49 weeks of DNL310 (ETV:IDS) treatment in the Phase 1/2 study, positive changes across…
MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
NEWS RELEASEFEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET Company to Host Conference Call…
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to…
Nephros Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call
SOUTH ORANGE, NJ, Feb. 22, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Nephros, Inc. (Nasdaq: NEPH), a leading…
Societal CDMO to Report Financial Results for Fourth Quarter and Year-End 2022 on March 1, 2023
Webcast Scheduled for Wednesday, March 1, 2023, at 4:30 p.m. Eastern SAN DIEGO and GAINESVILLE,…
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading…
23andMe to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME)…
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints…
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical…
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or…